Why do healthcare compliance programmes need to treat data access and data use as separate control problems?

Because a system can restrict access to PHI and still allow unsafe use through overbroad sharing, weak consent handling, or poorly governed analytics. Compliance requires controlling both who can reach data and what they are allowed to do with it. That distinction becomes critical when patient data is reused across systems, vendors, and AI workflows.

Why This Matters for Security Teams

Healthcare programmes cannot rely on a single “access granted” decision to prove compliance, because PHI can be reached legitimately and still be misused through overbroad disclosure, secondary analytics, weak consent enforcement, or vendor reuse. The control problem is split between access and use. That split is reflected in the NIST Cybersecurity Framework 2.0 and the OWASP Non-Human Identity Top 10, both of which reinforce that identity and authorization failures often emerge after an initial “valid” login or token use.

NHIMG research shows why the distinction matters in practice: 97% of non-human identities carry excessive privileges, and 90% of IT leaders say proper NHI management is essential for zero trust. In healthcare, those same overprivileged service accounts, API keys, and analytics pipelines can move PHI far beyond the original purpose of collection. The result is not just technical exposure, but audit, consent, and patient trust failures. NHIMG has also documented how governance gaps surface across lifecycle and audit stages in the Ultimate Guide to NHIs — Regulatory and Audit Perspectives.

In practice, many healthcare compliance teams discover unsafe data use only after a vendor, analyst, or automation has already replicated PHI into a downstream workflow.

How It Works in Practice

Strong healthcare governance separates the question “Can this user, service, or tool reach the record?” from “What may it do with the record once it has it?” Access controls answer the first question through authentication, RBAC, least privilege, network segmentation, and zero trust. Use controls answer the second through purpose limitation, consent checks, masking, redaction, retention limits, and rules for secondary processing. For AI-enabled workflows, this becomes even more important because a workflow can be technically authorised to read data while still being inappropriate to summarise, train on, or send to another system.

A practical control model often includes:

• Identity-bound access to PHI with scoped tokens and short-lived credentials for each task.
• Policy checks that evaluate purpose, patient consent, data class, and downstream destination at request time.
• Data handling rules that distinguish read-only access from export, inference, aggregation, and sharing.
• Logging that records both who accessed the data and how the data was transformed or reused.
• Review gates for third parties, analytics teams, and AI pipelines that may have legitimate access but constrained use rights.

That approach aligns with the control logic in Ultimate Guide to NHIs — Lifecycle Processes for Managing NHIs, especially where service accounts and API keys mediate clinical integrations. It also fits the implementation direction implied by NIST SP 800-53 Rev 5 Security and Privacy Controls, which separates access enforcement from information flow and privacy obligations. In healthcare, that distinction is what prevents a permitted login from becoming an impermissible disclosure. These controls tend to break down in federated data exchanges and AI pipelines because purpose, consent, and destination are not consistently preserved across systems.

Common Variations and Edge Cases

Tighter use controls often increase workflow friction, requiring organisations to balance clinical agility against privacy, auditability, and vendor speed. That tradeoff is real in emergency care, research, revenue cycle operations, and population health analytics, where broad access may be operationally convenient but still unacceptable for unrestricted use. Current guidance suggests there is no universal standard for every scenario, so healthcare teams should calibrate controls to data sensitivity, regulatory context, and downstream risk.

One edge case is “minimum necessary” access during treatment. Clinicians may need rapid access to broad PHI, but that does not imply unrestricted reuse by adjacent systems, labs, or AI copilots. Another is de-identified or pseudonymised data: access may be granted more broadly, but re-identification risk, linkage risk, and contractual limits still govern use. A third is third-party SaaS and model tooling, where a service account may be permitted to ingest records but not retain them, train on them, or mirror them outside the covered environment.

For this reason, healthcare programmes should treat access reviews, consent management, data classification, and vendor oversight as related but separate controls. NHIMG’s Top 10 NHI Issues highlights how quickly secrets and service identities become overextended when governance is only focused on login rights. The practical test is simple: if a system can answer “yes” to access but cannot prove “yes” to use, compliance is incomplete.

Related resources from NHI Mgmt Group

• How should identity verification teams adapt their compliance controls for the UK Data Use and Access Act?
• What breaks when organisations treat the DVS trust mark as a branding exercise instead of a compliance control?
• Why do data classification levels matter for access control and monitoring?
• Should teams use separate controls for database metadata access and data access?